WideMed wins CE Mark for mobile sleep apnea monitor
WideMed plans to begin marketing the Morpheus Ox system in Europe and the Far East during the fourth quarter.
The Morpheus Ox system can monitor, measure, and analyze snores and send accurate data to a physician about the patient’s respiration, apnea, oxygen levels, and heartbeat during the night.
WideMed said that it plans to begin marketing the Morpheus Ox system in Europe and the Far East during the fourth quarter, and that it undergoing regulatory procedures with the Food and Drug Administration (FDA) to approve the device for marketing in the US.
WideMed’s share price rose 12.1% by mid-afternoon to NIS 0.65, giving a market cap of NIS 10.5 million.
Published by Globes [online], Israel business news